Jessie Jiang, Nicole Giunio-Zorkin, Victoria Su, Renée Dagenais
{"title":"Optimal Therapeutic Drug Monitoring Strategy for IV Aminoglycosides and IV Vancomycin in People with Cystic Fibrosis: A Systematic Review.","authors":"Jessie Jiang, Nicole Giunio-Zorkin, Victoria Su, Renée Dagenais","doi":"10.4212/cjhp.3429","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Given altered pharmacokinetics in people with cystic fibrosis (pwCF), there is debate regarding optimal strategies for therapeutic drug monitoring (TDM) for aminoglycosides and vancomycin administered intravenously.</p><p><strong>Objectives: </strong>To determine the TDM strategy for IV aminoglycosides and IV vancomycin associated with optimal clinical outcomes in pwCF.</p><p><strong>Data sources: </strong>Several databases (MEDLINE, Embase, CINAHL, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov ) were searched from inception to November 15, 2020, with searches rerun on February 13, 2023.</p><p><strong>Study selection and data extraction: </strong>Full articles evaluating TDM strategies and clinical outcomes in pwCF receiving IV aminoglycosides or IV vancomycin were included.</p><p><strong>Data synthesis: </strong>Three studies met the inclusion criteria for IV aminoglycosides, and 1 study met the inclusion criteria for IV vancomycin. Data are presented with descriptive analyses.</p><p><strong>Conclusions: </strong>The available evidence is insufficient to determine an optimal TDM strategy for IV aminoglycoside or IV vancomycin therapy in pwCF.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Canadian journal of hospital pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4212/cjhp.3429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Given altered pharmacokinetics in people with cystic fibrosis (pwCF), there is debate regarding optimal strategies for therapeutic drug monitoring (TDM) for aminoglycosides and vancomycin administered intravenously.
Objectives: To determine the TDM strategy for IV aminoglycosides and IV vancomycin associated with optimal clinical outcomes in pwCF.
Data sources: Several databases (MEDLINE, Embase, CINAHL, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov ) were searched from inception to November 15, 2020, with searches rerun on February 13, 2023.
Study selection and data extraction: Full articles evaluating TDM strategies and clinical outcomes in pwCF receiving IV aminoglycosides or IV vancomycin were included.
Data synthesis: Three studies met the inclusion criteria for IV aminoglycosides, and 1 study met the inclusion criteria for IV vancomycin. Data are presented with descriptive analyses.
Conclusions: The available evidence is insufficient to determine an optimal TDM strategy for IV aminoglycoside or IV vancomycin therapy in pwCF.
背景：考虑到囊性纤维化（pwCF）患者的药代动力学改变，关于静脉注射氨基糖苷类和万古霉素的治疗药物监测（TDM）的最佳策略存在争议。目的：确定静脉注射氨基糖苷类药物和静脉注射万古霉素的TDM策略与pwCF的最佳临床结果相关。数据来源：从开始到2020年11月15日，搜索了几个数据库（MEDLINE、Embase、CINAHL、Web of Science、Cochrane Central Register of Controlled Trials.gov），并于2月13日重新运行搜索，2023.研究选择和数据提取：纳入了评估静脉注射氨基糖苷类或静脉注射万古霉素的pwCF的TDM策略和临床结果的完整文章。数据综合：3项研究符合静脉注射氨基糖苷类药物的纳入标准，1项研究符合血管注射万古霉素的纳入标准。数据采用描述性分析。结论：现有证据不足以确定静脉注射氨基糖苷类药物或静脉注射万古霉素治疗pwCF的最佳TDM策略。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
